Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
Identifieur interne : 000741 ( Main/Exploration ); précédent : 000740; suivant : 000742Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
Auteurs : David Devos [France] ; L. Defebvre [France] ; R. Bordet [France]Source :
- Fundamental & Clinical Pharmacology [ 0767-3981 ] ; 2010-08.
English descriptors
Abstract
Gait disorders form one component of the axial disorders observed in Parkinson’s disease (PD). Indeed, short steps with a forward‐leaning stance are diagnostic criteria for PD in the early stages of the condition. Gait disorders also represent a major source of therapeutic failure in the advanced stages of PD (with the appearance of freezing of gait and falls) because they do not respond optimally to the two hand late‐stage therapeutics – levodopa and electrical subthalamic nucleus (STN) stimulation. The late onset of doparesistance in these disorders may be linked to propagation of neurodegeneration to structures directly involved in gait control and to non‐dopaminergic neurotransmitter systems. The coeruleus locus (a source of noradrenaline) is rapidly and severely affected, leading to a major motor impact. The pedunculopontine nucleus (PPN) and lateral pontine tegmentum (rich in acetylcholine) are both involved in gait. Degenerative damage to the serotoninergic raphe nuclei appears to be less severe, although serotonin‐dopamine interactions are numerous and complex. Lastly, dopaminergic depletion leads to glutamatergic hyperactivity of the efferent pathways from the the STN to the PPN. However, the relationships between the various parkinsonian symptoms (and particularly gait disorders) and these pharmacological targets have yet to be fully elucidated. The goal of this review is to develop the various pathophysiological hypotheses published to date, in order to underpin and justify ongoing fundamental research and clinical trials in this disease area.
Url:
DOI: 10.1111/j.1472-8206.2009.00798.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L." last="Defebvre">L. Defebvre</name></author><author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R." last="Bordet">R. Bordet</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E30C8267F686573C916FD9B8D19D566FFA36D320</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1472-8206.2009.00798.x</idno><idno type="url">https://api.istex.fr/document/E30C8267F686573C916FD9B8D19D566FFA36D320/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000582</idno><idno type="wicri:Area/Main/Curation">000507</idno><idno type="wicri:Area/Main/Exploration">000741</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology and Movement Disorders, EA2683, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille</wicri:regionArea><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L." last="Defebvre">L. Defebvre</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology and Movement Disorders, EA2683, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille</wicri:regionArea><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R." last="Bordet">R. Bordet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Pharmacology Medical, EA 1046, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille</wicri:regionArea><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Fundamental & Clinical Pharmacology</title><idno type="ISSN">0767-3981</idno><idno type="eISSN">1472-8206</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-08">2010-08</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="407">407</biblScope><biblScope unit="page" to="421">421</biblScope></imprint><idno type="ISSN">0767-3981</idno></series><idno type="istex">E30C8267F686573C916FD9B8D19D566FFA36D320</idno><idno type="DOI">10.1111/j.1472-8206.2009.00798.x</idno><idno type="ArticleID">FCP798</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0767-3981</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>dopamine</term><term>gait disorders</term><term>glutamate</term><term>noradrenaline</term><term>pharmacology</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Gait disorders form one component of the axial disorders observed in Parkinson’s disease (PD). Indeed, short steps with a forward‐leaning stance are diagnostic criteria for PD in the early stages of the condition. Gait disorders also represent a major source of therapeutic failure in the advanced stages of PD (with the appearance of freezing of gait and falls) because they do not respond optimally to the two hand late‐stage therapeutics – levodopa and electrical subthalamic nucleus (STN) stimulation. The late onset of doparesistance in these disorders may be linked to propagation of neurodegeneration to structures directly involved in gait control and to non‐dopaminergic neurotransmitter systems. The coeruleus locus (a source of noradrenaline) is rapidly and severely affected, leading to a major motor impact. The pedunculopontine nucleus (PPN) and lateral pontine tegmentum (rich in acetylcholine) are both involved in gait. Degenerative damage to the serotoninergic raphe nuclei appears to be less severe, although serotonin‐dopamine interactions are numerous and complex. Lastly, dopaminergic depletion leads to glutamatergic hyperactivity of the efferent pathways from the the STN to the PPN. However, the relationships between the various parkinsonian symptoms (and particularly gait disorders) and these pharmacological targets have yet to be fully elucidated. The goal of this review is to develop the various pathophysiological hypotheses published to date, in order to underpin and justify ongoing fundamental research and clinical trials in this disease area.</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Lille</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></noRegion><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R." last="Bordet">R. Bordet</name><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L." last="Defebvre">L. Defebvre</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000741 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000741 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E30C8267F686573C916FD9B8D19D566FFA36D320
|texte= Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |